In our present study, four progression-related DE IRG (including VEGFA, SOCS3, SPP1, and TGFB2 genes)constituting a signature can perform risk stratification for glioma patients and disclosed that patients with high risk seemed to have an approximate 14.3%-29.8% 5-year survival rate. This evidence concerns the gene VEGFA and central nervous system cancer.